AVB-406: what AviadoBio reported, and what is still outstanding
AAV vMiX MAPT silencing in mice. AviadoBio / BioSpace release, 29 October 2026.
Mouse brain, 6 months
84% tau drop
One IV dose, endogenous tau protein
MAPT mRNA
Up to 79%
Dose-dependent knockdown
miRNA restricted to the CNS
Clinical entry
2027 plan
GLP toxicology ongoing
Not yet in human trials
Sponsor-reported preclinical findings. These results do not establish patient benefit or permission to start a trial.
Figures as reported by AviadoBio on 29 October 2026. Preclinical only; first-in-human remains a company plan.
Tau down 84% in mice at six months.
GLP toxicology is still running.
AviadoBio reported on 29 October that one intravenous dose of AVB-406, its AAV MAPT silencing therapy, kept tau protein 84% lower in mice at six months (company release). GLP toxicology is ongoing and the company plans first-in-human studies in 2027.
What was reported
AviadoBio presented new preclinical data for AVB-406 at the ESGCT Annual Congress. AVB-406 is described as an investigational, one-time intravenous gene therapy that silences MAPT, the tau gene, for Alzheimer's disease and other tauopathies.
The release says AVB-406 combines the company's vMiX RNA interference platform with a blood-brain barrier-penetrant AAV capsid and a neuron-specific promoter. In human neurons, the company reports that AVB-406 selectively reduced MAPT expression with no off-target changes in gene expression.
In mice, a single intravenous dose produced dose-dependent MAPT mRNA knockdown of up to 79% in the brain, with miRNA expression restricted to the central nervous system. Six months after one dose, the company reports maintained knockdown and an 84% reduction in endogenous tau protein.
In a mouse model of tauopathy, a vMiX MAPT-silencing construct reduced total brain tau by up to 94% and pathological cortical tau by up to 86%. The company says AVB-406 was well tolerated across animal studies to date, with no adverse clinical signs, while GLP toxicology studies are ongoing.
The same release also reports early AVB-SNCA data. The company reports approximately 80% SNCA mRNA silencing in testing that included human iPSC-derived neurons and up to 78% in a pilot in vivo study.
What this does and does not show
These are sponsor-reported preclinical findings from a press release. They do not show benefit in patients, and they are not permission to start a trial.
The release states that the 94% and 86% reductions came from a vMiX MAPT-silencing construct in a tauopathy model. It does not say that this construct is identical to AVB-406. Developers should not read those figures as AVB-406 efficacy.
The release gives no doses, vector genome numbers, group sizes or variability. It also does not say which species or studies the GLP program uses. The company's statement that doses are anticipated to be lower than approved systemic AAV therapies is an expectation, not a measured result.
What GTC would ask
For developers: how do the clinical capsid, promoter, dose and route map onto the material used in the mouse studies and in the ongoing GLP toxicology? A durable knockdown signal and an IND-ready package answer different questions.
For investors: which evidence packages still gate a 2027 first-in-human start? Toxicology is the one named as ongoing. Ask what else, including manufacturing of the clinical product, sits on the critical path.
Also ask how tau lowering is expected to translate into a clinical measure in early Alzheimer's disease. The release reports tau protein and mRNA in animals and says nothing about clinical endpoints.
Practical takeaway
Before accepting a clinical start date, ask for one evidence map that links the proposed clinical product to toxicology, dose selection and unresolved regulatory questions. If the team cannot draw that map, the date is a plan, not a milestone.
Related GTC reading
Frequently asked questions
What did AviadoBio report for AVB-406?
AviadoBio reported that one intravenous dose of AVB-406 produced dose-dependent MAPT mRNA knockdown of up to 79% in mouse brain. At six months it reported maintained knockdown and an 84% reduction in endogenous tau protein. These are sponsor-reported preclinical findings.
Is AVB-406 in clinical trials?
No. AviadoBio says GLP toxicology studies are ongoing and plans to advance AVB-406 into first-in-human studies for early Alzheimer's disease in 2027. AVB-406 is investigational and is not approved.
What is the vMiX platform?
The company describes vMiX as a vectorized RNA interference platform that uses an AAV vector to deliver gene silencing instructions. It is designed to give durable reduction of disease-causing gene expression after a single administration.
Do the mouse results show AVB-406 will work in patients?
No. Preclinical tau lowering in mice does not establish clinical benefit or safety in people. The release reports no clinical endpoints, and the largest tau reductions it cites came from a vMiX construct in a tauopathy model.
What is AVB-SNCA?
AVB-SNCA is a second vMiX program aimed at lowering SNCA expression for synucleinopathies including Parkinson's disease. The company reports approximately 80% SNCA mRNA silencing in testing that included human iPSC-derived neurons and up to 78% in a pilot in vivo study.
Sources
Join the GTC Expert Network
Independent Experts
Independent experts in cell & gene therapy: share knowledge, help build a report, or contribute quietly. Build authority and get called for paid consulting work. Join free.
Early R&D Experts
Early R&D ExpertsContribute target validation, vector engineering, or transgene design expertise. Get matched to paid consulting work through content you help create.
Join FreeCMC Experts
CMC ExpertsContribute scale-up, tech transfer, or GMP manufacturing expertise. Get matched to paid consulting work through content you help create.
Join FreeRegulatory Affairs Experts
Regulatory Affairs ExpertsContribute IND/BLA strategy or regulatory liaison expertise. Get matched to paid consulting work through content you help create.
Join FreeCommercial & Strategy Experts
Commercial & Strategy ExpertsContribute due diligence, licensing, or market access expertise. Get matched to paid consulting work through content you help create.
Join FreeEnabling Technology Experts
Enabling Technology ExpertsContribute bioprocessing hardware, analytical tooling, or supply-chain expertise. Get matched to paid consulting work through content you help create.
Join FreeAI Transformation Experts
AI Transformation ExpertsContribute agentic workflow, LLM, or AI-driven vector design expertise. Get matched to paid consulting work through content you help create.
Join FreeIndustry Representatives
Industry professionals in cell & gene therapy: de-risk your pipeline with expert input on demand, exactly when your program needs it. Join free.
Drug Developers
Drug DevelopersFounders, CSOs, VPs of R&D
Practical guides spanning vector design through commercialization, plus direct access to the expert network that wrote them.
Join FreeInvestors / VCs
Investors / VCsVC Fund Managers, Family Offices, Angels
Due diligence frameworks and strategic intelligence for evaluating CGT assets, from experts who do this diligence for a living.
Join FreeTechnology Developers
Technology DevelopersFounders, Licensing & Commercial Leads
IP protection and platform strategy guides for enabling technologies, plus the network that built them.
Join FreeCDMOs / CROs
CDMOs / CROsBD, Operations & Technical Leads
Partner selection, vendor evaluation, and operational excellence guides, sourced from the CGT organisations that use them.
Join FreeVendors / Suppliers
Vendors / SuppliersCommercial & Technical Leads
Market intelligence and partnership strategies for supply chain companies serving cell and gene therapy.
Join FreeStrategy Consultants
Strategy ConsultantsConsultants, Market Access Advisors
Spot the problems before they cost your clients - join the network that shapes what GTC covers next.
Join FreeAI Transformation Partners
AI Transformation PartnersAI/ML Consultancies, Digital Transformation Firms
AI education, implementation, and consulting for operational excellence in cell and gene therapy - for companies building or buying AI capability.
Join FreeWhere the analysis comes from. Industry teams get expert input on demand; independent experts build authority and get called for paid consulting work.
See more of our work in Google Search
Google lets you pick the sites you want to see more often in Top Stories. Add Gene Therapy Consultancy to your list, and our daily gene therapy news will show up higher for you.